Have an attendance code?
To be marked as completing this webinar archive, please enter the Attendance Code "072022" in the box above and view the archive.
Recordings are usually available 3-5 business days following the live presentation. Please continue to check this page for updates.
Have additional questions for the speaker? Send your questions to
webinars@osseo.org.
Description
Medication-related osteonecrosis of the jaw still poses major challenges for both patients and practitioners, as therapeutic measures must always be weighed up on a patient-specific basis in the overall context of the underlying diseases. However, in the almost 20 years since the first description of a relationship between the use of antiresorptive drugs and the development of the osteonecrosis of the jaw, significant progress has been made with regard to the perception, prevention and treatment of this disease. Although a multifactorial pathogenesis is very likely, there is increasing evidence in the literature that infections in the jaw region could play a key role in the development of the disease. As a result, preventive measures, early diagnosis and treatment are becoming increasingly important. Therefore, a good interdisciplinary exchange between all disciplines involved is of particular importance.
Upon completion of this presentation, participants should be able to: 1) describe and recognise the clinical picture of MRONJ; 2) identify the likely triggering factor in the multifactorial pathogenesis cascade; 3) recognize the two windows of prevention and the appropriate measures to reduce the risk of developing MRONJ; and 4) explain the current therapy options for the individual patient case with manifest MRONJ.